Gilead Sciences has been dominating the hepatitis C drug market.
Photograph by David Paul Morris — Bloomberg via Getty Images
By Scott DeCarlo and Jen Wieczner
April 29, 2015

Talk about a drug industry blockbuster. Over the past decade the market value of Fortune 500 pharmaceutical companies has nearly doubled, to $1.5 trillion, thanks largely to the explosive growth of biotechnology firms. In 2004 there was just one true biotech name—Amgen—on the list. Today there are seven, with a combined market cap that is fast approaching that of the old-guard Big Pharma companies.

Data source by FactSet. Chart by Nicolas Rapp and Analee Kasudia.

This story is from the May 1, 2015 issue of Fortune magazine.

SPONSORED FINANCIAL CONTENT

You May Like

EDIT POST